Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ceforanide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 10/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.57 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.57 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 9/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ceforanide SCHEMBL14303761 | 1.00 | TDP1 (1.00) | TDP1HSD17B10LMNAKDM4EMEN1 | |
| Ceforanide SCHEMBL10760121 | 1.00 | TDP1 (1.00) | TDP1HSD17B10LMNAKDM4EMEN1 | |
| Ceforanide SCHEMBL10760133 | 1.00 | TDP1 (1.00) | TDP1HSD17B10LMNAKDM4EMEN1 | |
| Ceforanide SCHEMBL27820426 | 0.99 | TDP1 (0.98) | TDP1HSD17B10LMNAKDM4EMEN1 | |
| Ceforanide SCHEMBL28528800 | 0.99 | TDP1 (0.98) | TDP1HSD17B10LMNAKDM4EMEN1 | |
| Ceforanide SCHEMBL9390322 | 0.94 | TDP1 (0.88) | TDP1HSD17B10LMNAKDM4EMEN1 | |
| SCHEMBL11395464 | 0.93 | TDP1 (0.88) | TDP1HSD17B10LMNAKDM4EMEN1 | |
| Ceforanide SCHEMBL11668090 | 0.93 | TDP1 (0.88) | TDP1HSD17B10LMNAKDM4EMEN1 | |
| Ceforanide SCHEMBL9390332 | 0.93 | TDP1 (0.87) | TDP1HSD17B10LMNAKDM4EMEN1 | |
| Ceforanide SCHEMBL10764451 | 0.93 | TDP1 (0.87) | TDP1HSD17B10LMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8952 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250222118-A1 | Beta-Lactam-Cannabinoid Conjugate Molecules | DIVERSE BIOTECH INC (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12310934-B2 | Methods of treatment of spontaneous preterm birth | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-27 | — | — | US | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| EP-0214898-A2 | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | claimed |
| EP-0084925-B1 | 6-AMINOALKYLPENICILLANIC ACID 1,1-DIOXIDES AND DERIVATIVES AS BETA-LACTAMASE INHIBITORS | PFIZER INC. (US) | 1986-04-09 | — | — | EP | claimed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | claimed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | claimed |
| US-4503040-A | 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1985-03-05 | — | — | US | claimed |
| US-4452796-A | ANTIBIOTICS | PFIZER INC. (US) | 1984-06-05 | — | — | US | claimed |
| US-4448958-A | SALT FORMATION WITH BENZYLDIMETHYLAMINE, DISSOLVING AND ADJUSTMENT OF PH TO CRYSTALLIZE | BRISTOL-MYERS COMPANY (US) | 1984-05-15 | — | — | US | claimed |
| EP-0106369-A2 | Purification of ceforanide | Bristol-Myers Company (US) | 1984-04-25 | — | — | EP | claimed |
| US-4427678-A | 6-Aminomethylpenicillanic acid 1,1-dioxide derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1984-01-24 | — | — | US | claimed |
| EP-0084925-A1 | 6-Aminoalkylpenicillanic acid 1,1-dioxides and derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1983-08-03 | — | — | EP | claimed |